Peptide Profile
KLOW Blend
Multi-Peptide Research Blend
CLINICAL DEVELOPMENT STAGE:
Not Established
KLOW is an 80mg multi-peptide research blend containing GHK-Cu, BPC-157, TB-500, and KPV. Its individual components have been investigated across tissue repair, extracellular matrix remodeling, angiogenic, inflammatory signaling, and cellular-response pathways. The KLOW combination itself has not been established as a clinically validated formulation.
Compound Overview
Classification
Multi-Peptide Research Blend
Blend Composition
GHK-Cu 50mg · BPC-157 10mg · TB-500 10mg · KPV 10mg
Regulatory Status
KLOW is not an FDA-approved drug or an established clinical formulation. Its individual components have differing research and regulatory histories.
Targets / Receptors
Multiple molecular targets and signaling pathways associated with GHK-Cu, BPC-157, thymosin beta-4–related peptides, and KPV, including pathways involved in tissue remodeling, angiogenesis, inflammatory signaling, and cellular repair responses.
Research Focus
Tissue repair and regeneration; wound-healing and extracellular matrix remodeling; angiogenesis and vascular response; inflammatory signaling and immune modulation; cellular migration and repair processes; and gastrointestinal tissue-protection pathways.
Mechanism of Action
KLOW combines four research peptides with distinct proposed biological activities rather than acting through a single defined receptor or mechanism. GHK-Cu has been investigated in relation to extracellular matrix remodeling, wound-response signaling, angiogenesis, and gene expression. BPC-157 has been studied experimentally in tissue-repair and vascular-response models. TB-500 is associated with research involving thymosin beta-4–related pathways, including actin regulation, cell migration, and tissue repair. KPV, a tripeptide derived from α-melanocyte-stimulating hormone, has been investigated for effects on inflammatory signaling.
These mechanistic observations largely derive from research on the individual components. They should not be interpreted as demonstrating that the combined KLOW formulation produces the same effects.
Research Evidence
The components of KLOW have substantially different evidence bases. GHK-Cu has been investigated in laboratory and clinical research involving skin biology, wound repair, extracellular matrix regulation, and related processes. KPV has a body of preclinical research examining inflammatory pathways. BPC-157 has primarily been investigated in preclinical models, while human evidence remains limited. Research involving TB-500 should also be distinguished from research on the naturally occurring thymosin beta-4 molecule from which related peptide fragments are derived.
Evidence concerning the individual ingredients does not establish the safety, efficacy, pharmacology, or clinical effects of the four-component KLOW blend. The combined formulation should therefore be described as a research blend rather than as a clinically validated therapeutic combination.
Safety & Limitations
Published evidence does not establish the safety, efficacy, dosing, pharmacokinetics, or long-term effects of the KLOW combination in humans. Evidence concerning individual components varies considerably in quality and clinical relevance and cannot be assumed to apply to the combined formulation. KLOW is intended for research use only and is not intended for human consumption, diagnosis, treatment, cure, or prevention of disease.
Key References
GHK-Cu
Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969–988. DOI: 10.1163/156856208784909435.
View on PubMed
Supports discussion of GHK-Cu in extracellular-matrix remodeling, inflammatory processes, angiogenesis, and tissue-repair research.
BPC-157
Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. 2019;377:153–159.
View on PubMed
A useful critical review of BPC-157 research involving tendon, ligament, skeletal muscle, and other soft-tissue models. The authors specifically note that most evidence comes from small-animal studies and that efficacy had not been confirmed in humans.
Thymosin β4 / TB-500-related research
Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005;11(9):421–429. DOI: 10.1016/j.molmed.2005.07.004.
View on PubMed
Reviews thymosin β4’s biochemical properties, actin interaction, and research concerning tissue repair and remodeling.
KPV
Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews. 2008;29(5):581–602.
View on PubMed
Reviews α-MSH-related pathways and KPV specifically, including experimental evidence involving inflammatory signaling.
KPV — experimental model
Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324–331. DOI: 10.1002/ibd.20334.
View on PubMed
Provides direct preclinical research on KPV in murine inflammatory models.
Evidence note: References above concern the individual components of the KLOW formulation. They do not establish the safety, efficacy, or biological effects of the combined KLOW blend.
Last scientifically reviewed: 10/08/2026